TABLE OF CONTENTS
SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. EXECUTIVE’S HANDBOOK
1.1. The Top Performing Segments
1.2. Key Trends Summarized
1.3. Pricing Outlook
1.4. Strategic Insights
1.5. Who are the Key Players in the Market?
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Report Segmentation & Scope
2.3. Regional & Country Level Coverage
2.4. Why you need this report?
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Flow
3.2.1. Data Mining Process
3.3. Purchased Database:
3.4. Secondary Sources:
3.4.1. Secondary Research Data Flow:
3.5. Primary Research:
3.5.1. Primary Research Data Flow:
3.5.2. Primary Research: Number Of Interviews Conducted
3.5.3. Primary Research: Regional Coverage
3.6. Approaches For Market Size Estimation:
3.6.1. Revenue Analysis Approach
3.7. Data Forecasting
3.7.1. Data Forecasting Technique
3.8. Data Modeling
3.8.1. Microeconomic Factor Analysis:
3.8.2. Data Modeling:
3.9. Teams and Analyst Contribution
SECTION III: QUALITATIVE ANALYSIS
4. MARKET DYNAMICS
4.1. Introduction
4.2. Growth Parameters Mapped - Drivers
4.2.1. Growth in the Pharmaceutical Industry Supplementing Sales to the Significant Extent
4.2.2. Adoption of smarter cold chain technology
4.3. What are the challenges faced by Industry Participants?
4.3.1. Rise in raw material costs
4.4. Opportunities
4.4.1. Various government initiatives are carried out by various countries to boost the pharmaceutical industry.
4.5. Impact analysis of covid-19
4.5.1 economic impact
4.5.1.1 impact on the packaging industry
4.5.2 Impact on production
4.5.3 Impact on temperature-controlled packaging for the pharmaceutical industry
4.5.3.1 impact on supply chain
4.5.3.2 impact on raw materials
4.5.3.3 cash flow constraints
4.5.1. Impact on world trade
5. MARKET FACTOR ANALYSIS
5.1. Supply/Value Chain Analysis
5.1.1. Participants
5.1.2. Value Percolation Across the Chain
5.1.3. Integration Levels
5.1.4. Key Issues Addressed
5.2. Porter’s Five Forces Model
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
SECTION IV: QUANTITATIVE ANALYSIS
6. GLOBAL TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY PRODUCT
6.1. Introduction
6.2. Shippers
6.3. Containers
7. GLOBAL TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY TYPE
7.1. Automotive
7.2. Active System
7.3. Passive System
8. GLOBAL TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY TEMPERATURE RANGE
8.1. Introduction
8.2. -20°C AND BELOW
8.3. -20°C TO 0°C
8.4. 2°C TO 8°C
8.5. 8°C TO 25°C
8.6. ABOVE 25°C
9. GLOBAL TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY PAYLOAD CAPACITY
9.1. Introduction
9.2. UP TO 10 L
9.3. 10 L - 20 L
9.4. 20 L - 40 L
9.5. 40 L - 150 L
9.6. ABOVE 150 L
10. GLOBAL TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY USE
10.1. Introduction
10.2. Single Use
10.3. Reusable
11. GLOBAL TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY MEDICINE TYPE
11.1. Introduction
11.2. Temperature Sensitive Pharmaceutical Drugs
11.3. Vaccine
11.4. Regenerative Medicine
12. GLOBAL TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY END-USE INDUSTRY
12.1. Introduction
12.2. Pharmaceuticals
12.3. Clinical Trails
13. GLOBAL TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY REGION
13.1. Introduction
13.2. North America
13.2.1. U.S.
13.2.2. Canada
13.3. Europe
13.3.1. Germany
13.3.2. France
13.3.3. U.K.
13.3.4. Italy
13.3.5. Spain
13.3.6. Rest Of Europe
13.4. Asia Pacific
13.4.1. China
13.4.2. Japan
13.4.3. India
13.4.4. South Korea
13.4.5. Taiwan
13.4.6. Philippines
13.4.7. Indonesia
13.4.8. Thailand
13.4.9. Malaysia
13.4.10. Singapore
13.4.11. Hong Kong
13.4.12. Australia
13.4.13. Rest Of Asia-Pacific
13.5. Rest of the World
13.5.1. Middle East & Africa
13.5.2. South America
SECTION V: COMPETITIVE ANALYSIS
14. COMPETITIVE LANDSCAPE
14.1. Introduction
14.2. Competition Dashboard
14.3. Company Market Share Analysis, 2023
14.4. Who are the market disruptors & innovators?
14.5. What strategies are being adopted by market leaders?
14.6. The Leading Player in terms of Number of Developments in the Market
14.7. Competitive Benchmarking
14.8. Public Players Stock Summary
14.9. Comparative Analysis: Key Players Financial
14.10. Key Developments & Growth Strategies
14.10.1. Product Developments
14.10.2. Merger & Acquisition
14.10.3. Expansion
15. COMPANY PROFILES
15.1. Cold Chain Technologies, LLC
15.1.1. Company Overview
15.1.2. Financial Overview
15.1.3. Product Offered
15.1.4. Key Developments
15.1.5. SWOT Analysis
15.1.6. Key Strategies
15.2. EMBALL’ISO
15.2.1. Company Overview
15.2.2. Financial Overview
15.2.3. Product Offered
15.2.4. Key Developments
15.2.5. SWOT Analysis
15.2.6. Key Strategies
15.3. Inmark, LLC
15.3.1. Company Overview
15.3.2. Financial Overview
15.3.3. Product Offered
15.3.4. Key Developments
15.3.5. SWOT Analysis
15.3.6. Key Strategies
15.4. Sonoco Thermosafe
15.4.1. Company Overview
15.4.2. Financial Overview
15.4.3. Product Offered
15.4.4. Key Developments
15.4.5. SWOT Analysis
15.4.6. Key Strategies
15.5. va-Q-tec AG
15.5.1. Company Overview
15.5.2. Financial Overview
15.5.3. Product Offered
15.5.4. Key Developments
15.5.5. SWOT Analysis
15.5.6. Key Strategies
15.6. Deutsche Bahn AG
15.6.1. Company Overview
15.6.2. Financial Overview
15.6.3. Product Offered
15.6.4. Key Developments
15.6.5. SWOT Analysis
15.6.6. Key Strategies
15.7. DHL International GmbH
15.7.1. Company Overview
15.7.2. Financial Overview
15.7.3. Product Offered
15.7.4. Key Developments
15.7.5. SWOT Analysis
15.7.6. Key Strategies
15.8. kuehne + nagel inc.
15.8.1. Company Overview
15.8.2. Financial Overview
15.8.3. Product Offered
15.8.4. Key Developments
15.8.5. SWOT Analysis
15.8.6. Key Strategies
15.9. UNITED PARCEL SERVICE OF AMERICA, INC.
15.9.1. Company Overview
15.9.2. Financial Overview
15.9.3. Product Offered
15.9.4. Key Developments
15.9.5. SWOT Analysis
15.9.6. Key Strategies
15.10. Kaneka Corporation
15.10.1. Company Overview
15.10.2. Financial Overview
15.10.3. Product Offered
15.10.4. Key Developments
15.10.5. SWOT Analysis
15.10.6. Key Strategies
15.11. CSafe Global
15.11.1. Company Overview
15.11.2. Financial Overview
15.11.3. Product Offered
15.11.4. Key Developments
15.11.5. SWOT Analysis
15.11.6. Key Strategies
16. RECOMMENDATIONS & EXPERT INSIGHTS
16.1. What is the short-term vs long-term outlook for Market?
16.2. Who are the players to look out for?
16.3. What will the product mix look in coming years?
17. MRFR OFFERINGS & TEAM
17.1. Citations & Media
17.2. Our Regional Representatives
17.3. Related Reports
17.4. Our Domain Coverage
LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS
TABLE 2 GLOBAL TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY PRODUCT 2018–2032 (USD MILLION)
TABLE 3 GLOBAL TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY TYPE 2018–2032 (USD MILLION)
TABLE 4 TEMPERATURE RANGE: GLOBAL TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY TEMPERATURE RANGE 2018–2032 (USD MILLION)
TABLE 5 TEMPERATURE RANGE: GLOBAL TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY PAYLOAD CAPACITY 2018–2032 (USD MILLION)
TABLE 6 GLOBAL TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY USE 2018–2032 (USD MILLION)
TABLE 7 GLOBAL TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY MEDICINE TYPE 2018–2032 (USD MILLION)
TABLE 8 REGENERATIVE MEDICINE: GLOBAL TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY MEDICINE TYPE 2018–2032 (USD MILLION)
TABLE 9 GLOBAL TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY END USE INDUSTRY 2018–2032 (USD MILLION)
TABLE 10 GLOBAL TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY REGION, 2018–2032 (USD MILLION)
TABLE 11 NORTH AMERICA: TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY COUNTRY, 2018–2032 (USD MILLION)
TABLE 12 NORTH AMERICA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY PRODUCT, 2018–2032 (USD MILLION)
TABLE 13 NORTH AMERICA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY TYPE 2018–2032 (USD MILLION)
TABLE 14 NORTH AMERICA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY TEMPERATURE RANGE 2018–2032 (USD MILLION)
TABLE 15 NORTH AMERICA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY PAYLOAD CAPACITY 2018–2032 (USD MILLION)
TABLE 16 NORTH AMERICA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY USE 2018–2032 (USD MILLION)
TABLE 17 NORTH AMERICA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY MEDICINE TYPE 2018–2032 (USD MILLION)
TABLE 18 REGENERATIVE MEDICINE: NORTH AMERICA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY MEDICINE TYPE 2018–2032 (USD MILLION)
TABLE 19 NORTH AMERICA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY END USE INDUSTRY 2018–2032 (USD MILLION)
TABLE 20 USA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY PRODUCT, 2018–2032 (USD MILLION)
TABLE 21 USA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY TYPE 2018–2032 (USD MILLION)
TABLE 22 USA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY TEMPERATURE RANGE 2018–2032 (USD MILLION)
TABLE 23 USA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY PAYLOAD CAPACITY 2018–2032 (USD MILLION)
TABLE 24 USA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY USE 2018–2032 (USD MILLION)
TABLE 25 USA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY MEDICINE TYPE 2018–2032 (USD MILLION)
TABLE 26 REGENERATIVE MEDICINE: USA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY MEDICINE TYPE 2018–2032 (USD MILLION)
TABLE 27 USA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY END USE INDUSTRY 2018–2032 (USD MILLION)
TABLE 28 CANADATEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY PRODUCT, 2018–2032 (USD MILLION)
TABLE 29 CANADA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY TYPE 2018–2032 (USD MILLION)
TABLE 30 CANADA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY TEMPERATURE RANGE 2018–2032 (USD MILLION)
TABLE 31 CANADA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY PAYLOAD CAPACITY 2018–2032 (USD MILLION)
TABLE 32 CANADA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY USE 2018–2032 (USD MILLION)
TABLE 33 CANADA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY MEDICINE TYPE 2018–2032 (USD MILLION)
TABLE 34 REGENERATIVE MEDICINE: USA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY MEDICINE TYPE 2018–2032 (USD MILLION)
TABLE 35 CANADA TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY END USE INDUSTRY 2018–2032 (USD MILLION)
TABLE 36 EUROPE: TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY COUNTRY, 2018–2032 (USD MILLION)
TABLE 37 EUROPE TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY PRODUCT, 2018–2032 (USD MILLION)
TABLE 38 EUROPE TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY TYPE 2018–2032 (USD MILLION)
TABLE 39 EUROPE TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY TEMPERATURE RANGE 2018–2032 (USD MILLION)
TABLE 40 EUROPE TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY PAYLOAD CAPACITY 2018–2032 (USD MILLION)
TABLE 41 EUROPE TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY USE 2018–2032 (USD MILLION)
TABLE 42 EUROPE TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY MEDICINE TYPE 2018–2032 (USD MILLION)
TABLE 43 REGENERATIVE MEDICINE: EUROPE TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY MEDICINE TYPE 2018–2032 (USD MILLION)
TABLE 44 EUROPE TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY END USE INDUSTRY 2018–2032 (USD MILLION)
TABLE 45 GERMANY TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY PRODUCT, 2018–2032 (USD MILLION)
TABLE 46 GERMANY TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY TYPE 2018–2032 (USD MILLION)
TABLE 47 GERMANY TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY TEMPERATURE RANGE 2018–2032 (USD MILLION)
TABLE 48 GERMANY TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY PAYLOAD CAPACITY 2018–2032 (USD MILLION)
TABLE 49 GERMANY TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY USE 2018–2032 (USD MILLION)
TABLE 50 GERMANY TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY MEDICINE TYPE 2018–2032 (USD MILLION)
TABLE 51 REGENERATIVE MEDICINE: GERMANY TEMPERATURE CONTROLLED PACKAGING FOR PHARMACEUTICAL MARKET, BY MEDICINE TYPE 2018–2
